Document Detail

New algorithm for OHSS prevention.
Jump to Full Text
MedLine Citation:
PMID:  22054506     Owner:  NLM     Status:  MEDLINE    
Ovarian hyperstimulation syndrome (OHSS) still remains a life-threatening complication of in vitro fertilization treatment (IVF), keeping patients and especially those, who previously experienced OHSS, from attempting infertility treatment and childbearing. The recent implementation of four new modalities: the GnRH antagonist protocol, GnRH agonist (GnRHa) triggering of ovulation, blastocyst transfer and embryo/oocyte vitrification, renders feasible the elimination of OHSS in connection with ovarian hyperstimulation for IVF treatment. The proposed current algorithm is based on the number of follicles developed after ovarian stimulation, setting a cut-off level at the development of 18 or more follicles. Further, fulfilling this criterion, the algorithm is based on four decision-making points: the final day of patient work-up, the day of triggering final oocyte maturation, day-1 post oocyte pick-up (OPU) and day-5 post OPU. If the physician decides to administer hCG for final oocyte maturation regardless the type of analogue used, he has the option on day-1 to either freeze all embryos or to proceed to day-5. On this day, based on the clinical condition of the patient, a decision should be made to either transfer a single blastocyst or to vitrify all blastocysts available. However, this strategy will not guarantee an OHSS free luteal phase especially if a pregnancy occurs. If the physician decides to trigger ovulation with GnRHa, feasible only with the antagonist protocol, embryos can be cultured until day-5. On this day a transfer can be performed with no risk of OHSS and spare blastocysts may be vitrified. Alternatively, on day-1 or day-2 post OPU, all embryos could be frozen. Hopefully, in a near future, GnRHa triggering and vitrification of oocytes will become everyday practice. Only the combined use of a GnRH antagonist protocol with GnRHa triggering and subsequent single blastocyst transfer or embryo/oocyte freezing will completely abolish the risk of OHSS after ovarian hyperstimulation.
Evangelos G Papanikolaou; Peter Humaidan; Nikos Polyzos; Sofia Kalantaridou; Sahar Kol; Claudio Benadiva; Herman Tournaye; Basil Tarlatzis
Related Documents :
943896 - A prospective study of drugs and pregnancy. ii. anti-emetic drugs.
2535936 - Correlation between selective inhibition of the cyclic nucleotide phosphodiesterases an...
2818116 - Outcomes of pregnancy in adolescents with severe asthma.
12948456 - The australian registry of anti-epileptic drugs in pregnancy: experience after 30 months.
2025036 - Iron supplementation, maternal packed cell volume, and fetal growth.
24678216 - Outcome of forceps delivery in a teaching hospital: a 2 year experience.
Publication Detail:
Type:  Journal Article     Date:  2011-11-03
Journal Detail:
Title:  Reproductive biology and endocrinology : RB&E     Volume:  9     ISSN:  1477-7827     ISO Abbreviation:  Reprod. Biol. Endocrinol.     Publication Date:  2011  
Date Detail:
Created Date:  2011-12-06     Completed Date:  2012-03-28     Revised Date:  2013-06-27    
Medline Journal Info:
Nlm Unique ID:  101153627     Medline TA:  Reprod Biol Endocrinol     Country:  England    
Other Details:
Languages:  eng     Pagination:  147     Citation Subset:  IM    
Human Reproduction & Genetics Foundation, Adrianoupoleos 6, 55133 Kalamaria, Thessaloniki, Greece.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cryopreservation / methods
Embryo Transfer
Embryo, Mammalian
Fertilization in Vitro / adverse effects,  methods*
Gonadotropin-Releasing Hormone / agonists,  antagonists & inhibitors
Hormone Antagonists / therapeutic use
Ovarian Follicle / cytology,  drug effects
Ovarian Hyperstimulation Syndrome / etiology,  prevention & control*
Ovulation Induction / adverse effects,  methods
Pregnancy Complications / etiology,  prevention & control*
Time Factors
Reg. No./Substance:
0/Hormone Antagonists; 33515-09-2/Gonadotropin-Releasing Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): Reprod Biol Endocrinol
ISSN: 1477-7827
Publisher: BioMed Central
Article Information
Download PDF
Copyright ©2011 Papanikolaou et al; licensee BioMed Central Ltd.
Received Day: 22 Month: 2 Year: 2011
Accepted Day: 3 Month: 11 Year: 2011
collection publication date: Year: 2011
Electronic publication date: Day: 3 Month: 11 Year: 2011
Volume: 9First Page: 147 Last Page: 147
ID: 3230134
Publisher Id: 1477-7827-9-147
PubMed Id: 22054506
DOI: 10.1186/1477-7827-9-147

New algorithm for OHSS prevention
Evangelos G Papanikolaou17 Email:
Peter Humaidan2 Email:
Nikos Polyzos3 Email:
Sofia Kalantaridou4 Email:
Sahar Kol5 Email:
Claudio Benadiva6 Email:
Herman Tournaye3 Email:
Basil Tarlatzis7 Email:
1Human Reproduction & Genetics Foundation, Adrianoupoleos 6, 55133 Kalamaria, Thessaloniki, Greece
2The Fertility Clinic Odense University Hospital (OUH) Boulevard 29, entrance 55 5000 Odense C, Denmark
3Centrum voor Reproductieve Geneeskunde, UZ Brussel, Flemish Free university of Brussels, Belgium
4Department of Obstetrics and Gynecology, University of Ioannina, Greece
5Department of Obstetrics and Gynecology, IVF Unit, Rambam Medical Center, Haifa, Israel
6Center for Advanced Reproductive Services, University of Connecticut School of Medicine, Department of Obstetrics and Gynecology, Farmington, Connecticut, USA
7Assisted Reproduction Unit, 1st Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Greece


The most feared complication of IVF-related ovarian stimulation for the patient as well as the doctor is the development of ovarian hyperstimulation syndrome (OHSS) [1]; a syndrome, which in its severe form leads to hospitalization and in the worst case scenario fatal complications. The incidence of clinically significant OHSS is 2-3%, however, milder forms of OHSS might develop in up to 20-30% of all IVF patients [2].

The basis for OHSS development is the development of multiple follicles. Once this criterion is fulfilled, the second factor needed for the development of the severe form of the disease is either the exogenous administration of HCG for final oocyte maturation - as is the current practice - or the establishment of a pregnancy and the production of endogenous HCG from the implanting embryo [3]. Therefore, two types of OHSS have been identified: the early onset OHSS which is self-limited in case no pregnancy occurs, and the late onset OHSS which develops ten days or more after the egg retrieval [4]. In contrast to the early OHSS the late onset OHSS is poorly correlated to the ovarian response after stimulation.

All late onset OHSS cases are related to pregnancy and these cases often require hospitalization. Unfortunately these late OHSS cases render the prediction of OHSS a difficult task [5] and the methods used to predict the condition prior to stimulation have been shown having limited success [6].

The protocol of choice for potential high-responder patients prone to develop OHSS should be the GnRH antagonist protocol, as it has been shown to decrease the incidence of OHSS significantly [7,8]. Furthermore, it allows the utilization of a GnRHa to induce final oocyte maturation, which has recently regained interest. The pooled evidence shows that by triggering with GnRHa in patients co-treated with a GnRH antagonist protocol, not only is OHSS minimized, but also this concept allows embryo transfer in the hyper-responding patient with a reproductive outcome comparable to that seen after hCG triggering as long as adequate luteal support can be achieved [9].

At the same time, the development of the vitrification procedure has improved the embryo survival rate as compared to the classical method of slow freezing [10]. Thus, considering the different modalities that the physician has available, we below propose an algorithm for OHSS high-risk patients. The algorithm may easily be applied according to the preferences of the doctor and his patient and refers to both GnRH-analogues, GnRH agonist as well as GnRH antagonist.


The algorithm is based on two decision making time periods: the follicular phase and the luteal phase; and four time-points: the final day of patient work-up, the day of ovulation triggering, day-1 post-OPU and day-5 post-OPU (Figure 1). However, the OHSS reducing strategy obviously already starts when the physician evaluates the patient's ovarian reserve and thus the risk for hyperstimulation prior to stimulation [6].

Final day of patient work-up (Decision point 1)

A mandatory step in the ovarian stimulation for IVF is firstly the gonadotropin dose and secondly the protocol. Regarding the prediction of hyper-response, recent evidence suggests the superiority of AMH over antral follicle count [11,12]. In a prospective cohort of 262 IVF cycles with 8% moderate and severe OHSS, Lee et al showed that an AMH cut-off value of 3.36 ng/mL gave a sensitivity of 90.5% and a specificity of 81.3% to predict OHSS [11,12]. Regarding the antral follicle count, Kwee et al have shown that a cut off level of > 14 antral follicles gave the highest sensitivity (82%) and specificity (89%) and also the highest accuracy. With a prevalence of 15% for high response (defined as > 20 oocytes in an IVF treatment), the accuracy was 88% [13]. According to these thresholds, a woman considered to be at high risk of developing OHSS should be stimulated with low doses of gonadotropins and preferably co-treated with a GnRH antagonist. Nevertheless, individualization of doses and protocol utilized depends on the clinical experience of the treating physician.

Although we use certain cut-off values and our clinical experience to avoid hyperstimulation, we many times fail and the patients ends-up with an excessive ovarian response. As mentioned, Papanikolaou and colleagues have shown that the first prerequisite for OHSS development is the development of multiple follicles and specifically more than 18 follicles with a diameter above 11 mm and/or above 5000 pg/ml Estradiol [2,14]. Thus, from the late follicular phase and onwards, it becomes clear which patient is potentially at high-risk of developing OHSS. Therefore, a modification of the ovarian stimulation should be applied, either decreasing the dose of gonadotropins or administering the triggering bolus of hCG earlier (when three follicles reach the size of 17 mm). In GnRH antagonist protocols, this has been shown to be more efficient compared to later administration at a larger follicular size [15,16]. Both these actions intend to induce the regression of small and medium sized follicles initially recruited, which will decrease the risk of OHSS.

Day of Triggering final oocyte maturation (Decision 2)

Once the patient has met the criterion set above, the clinician has two options for triggering ovulation: either to administer a lower dose of HCG (250 mcg rec-HCG or 3,300 to 5000 IU urinary hCG), which is the traditional way, applicable in GnRH agonist as well as GnRH antagonist protocols [16]; or to administer GnRHa for final oocyte maturation (0.2 mg Triptorelin or 0.5 mg Buserelin or 1 mg Leuprolide), the innovative way, applicable only in the Antagonist protocol [17].

(i) Traditional way with HCG-triggering

hCG for triggering of final oocyte maturation has been the gold standard treatment for decades, clinically approved and highly efficient. This triggering concept is the only one to be applied in patients co-treated with a long GnRH agonist protocol. However, OHSS may still occur despite administration of lower doses of hCG instead of the standard 10,000 IU dose [18]. Specifically in high-risk patients the OHSS incidence might reach up to 30% in case of embryo transfer and the achievement of a pregnancy [19]. On the other hand the presence of exogenous HCG for 8 days in circulation during the luteal phase [18] secures the appropriate function of the corpora lutea and hence the implantation of the transferred embryo.

(ii) Innovative way with GnRH Agonist triggering

the newer option, using GnRHa triggering, minimizes the risk of OHSS and secures the appropriate maturation of oocytes. The oocyte pick-up after GnRHa triggering should be performed within 34-35 hours. However, GnRHa triggering is possible only when using a GnRH antagonist protocol and requires modified luteal support in order to be as efficient as hCG triggering [19-21]. The complete eradication of OHSS has made the GnRHa triggering concept the protocol of choice in oocyte donation cycles [22]. In parallel, in IVF with fresh embryo transfer, a new meta-analysis indicates that if luteal support is modified with either a bolus of hCG on the day of OPU, alternate doses of rec-LH, or intense luteal support with intramuscular progesterone and estradiol patches, the delivery rate is comparable to that seen after hCG triggering [9].

Day-1 in luteal phase post-OPU (Decision 3)

On the first day after the oocyte retrieval, a decision should be made whether to proceed with luteal phase support and subsequently embryo transfer or to freeze all embryos. On this day, the physician will have performed an ultrasound measuring the quantity of fluid in the pouch of Douglas and the ovarian volume; he should also assess the physical condition of the patient i.e. the degree of pain, discomfort, use of painkillers, and breathing difficulty [15]. In addition, the number of fertilized oocytes will be known. Taking these facts into account and adding the efficacy of the cryopreservation program of the unit, a decision can be made whether to proceed with the embryo transfer or to freeze all embryos.

(i) Traditional way after HCG-triggering

If the patient on the planned day of triggering already has developed signs or symptoms of early OHSS it is advisable to freeze all embryos at the 2PN stage or at the cleavage stage (day-2/3) and to cancel the embryo transfer. With appropriate counseling the patient will not regard a total freeze as a failure, but rather as a preventive measure, ensuring her health. Importantly, with a good cryo-program her chances of obtaining a pregnancy will not be reduced [23]. Alternatively, given that the patient can tolerate a milder hyperstimulation, a blastocyst transfer can be planned, if her condition does not worsen during the observational period. Nevertheless, the risk of late onset OHSS cannot be excluded with this approach.

(ii) Innovative way after GnRH Agonist triggering

As mentioned above, in the new studies focusing on intense luteal support [19] or supplementation with LH-activity [20,21,24] pregnancy rates are comparable to the standard HCG triggering protocol and at the same time OHSS is eliminated. Therefore, a fresh embryo transfer with freezing of surplus embryos might be a more preferred strategy instead of a total freeze. Nevertheless, for those yet not convinced about the reproductive outcome after GnRH agonist triggering followed by modified luteal phase support, a total freeze is still an option.

Day-5 in luteal phase post-OPU (Decision 4)

Prior to a day-5 transfer, an ultrasound should be performed in combination with blood tests (Hematocrit, WBC, PLT, PT, aPTT, Fibrinogen, D-Dimers, Urea, Creatinine, ALT, AST, gGT, ALP, K, Na, Total Protein, Albumin) to identify patients at high risk of developing severe late onset OHSS. If the evaluation is reassuring a single blastocyst transfer can be performed, followed by vitrification of spare blastocysts [25]. If a patient is considered at high risk of developing OHSS - as might often be the case if hCG triggering has been utilized - the embryo transfer should be cancelled. For units working with slow freezing only or having low blastocyst development rates, an alternative option is to freeze half of the embryos at the cleavage stage and allow the rest to develop into blastocysts. If the condition of the patient permits it, a blastocyst transfer is performed and surplus embryos are cryopreserved.

(i) Traditional way after hCG-triggering

on day-5 if the patient confirms her good physical condition and blood tests and/or ultrasound examination are reassuring, a single blastocyst transfer should be performed. Possible supernumerary blastocysts should be vitrified. Importantly, the patient has to be informed that the risk of late OHSS still exists. In contrast, if the patient has developed signs of early onset OHSS, all blastocysts should be cryopreserved.

(ii) Innovative way after GnRH Agonist triggering

usually no signs of early OHSS will be present and hence the transfer of a single or even two blastocysts in older patients will not increase the risk of late onset OHSS [9]. Supernumerary blastocysts can be vitrified for future use.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

EGP conceived that concept and wrote the manuscript, PH wrote the manuscript, NPP revised the manuscript, SK revised the manuscript, SK revised the manuscript, HT revised the manuscript, CB wrote the manuscript, BT revised the manuscript. All authors read and approved the final manuscript.


We would like to thank Mrs. Vlachou Christina for analyzing reference papers and final editing of the manuscript.

Rizk B,Aboulghar MA,Brinsden PClassification, pathophysiology and management of ovarian hyperstimulation syndromeIn-Vitro Fertilization and Assisted ReproductionYear: 1999New York, NY: Parthenon Publishing Group131155
Papanikolaou EG,Pozzobon C,Kolibianakis EM,Camus M,Tournaye H,Fatemi HM,Van Steirteghem A,Devroey P,Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cyclesFertil SterilYear: 20068511212010.1016/j.fertnstert.2005.07.129216412740
Orvieto R,Can we eliminate severe ovarian hyperstimulation syndrome?Hum ReprodYear: 20052032032215567876
Mathur RS,Akande VA,Keay SD,Hunt LP,Jenkins JM,Distinction between early and late ovarian hyperstimulation syndromeFertil SterilYear: 20007390190710.1016/S0015-0282(00)00492-110785214
Kol S,Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!Hum ReprodYear: 2003181557155810.1093/humrep/deg30212832392
Papanikolaou EG,Humaidan P,Polyzos NP,Tarlatzis B,Identification of the high-risk patient for ovarian hyperstimulation syndrome: SeminReprod MedYear: 20102845846210.1055/s-0030-1265671
Griesinger G,Diedrich K,Tarlatzis BC,Kolibianakis EM,GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysisReprod Biomed OnlineYear: 20061362863810.1016/S1472-6483(10)60652-917169171
Al-Inany HG,Abou-Setta AM,Aboulghar M,Gonadotrophin-releasing hormone antagonists for assisted conception: a Cochrane reviewReprod Biomed OnlineYear: 20071464064910.1016/S1472-6483(10)61059-017509210
Humaidan P,Kol S,Papanikolaou EG,on behalf of the "The Copenhagen GnRH Agonist Triggering Workshop GroupGnRH agonist for triggering of final oocyte maturation: time for a change of practice?Hum Reprod UpdateYear: 20111751052410.1093/humupd/dmr00821450755
Loutradi KE,Kolibianakis EM,Venetis CA,Papanikolaou EG,Pados G,Bontis I,Tarlatzis BC,Cryopreservation of human embryos by vitrification or slow freezing: a systematic review and meta-analysisFertil SterilYear: 20089018619310.1016/j.fertnstert.2007.06.01017980870
Lee TH,Liu CH,Huang CC,Wu YL,Shih YT,Ho HN,Yang YS,Lee MS,Serum anti-Müllerian hormone and estradiol levels as predictors of ovarian hyperstimulation syndrome in assisted reproduction technology cyclesHum ReprodYear: 20082316016718000172
La Marca A,Giulini S,Tirelli A,Bertucci E,Marsella T,Xella S,Volpe A,Anti-Müllerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technologyHum ReprodYear: 20072276677017071823
Kwee J,Elting ME,Schats R,McDonnell J,Lambalk CB,Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilizationReprod Biol EndocrinolYear: 200715;5922053725
Papanikolaou EG,Tournaye H,Verpoest W,Camus M,Vernaeve V,Van Steirteghem A,Devroey P,Early and late ovarian hyperstimulation syndrome: early pregnancy outcome and profileHum ReprodYear: 20052063664110.1093/humrep/deh63815576388
Humaidan P,Quartarolo J,Papanikolaou EG,Preventing ovarian hyperstimulation syndrome: guidance for the clinicianFertil SterilYear: 20109438940010.1016/j.fertnstert.2010.03.02820416867
Schmidt D,Maier D,Nulsen J,Benadiva CA,Reducing the dose of hCG in high responders does not affect the outcomes of in vitro fertilizationFertil SterilYear: 20048284184610.1016/j.fertnstert.2004.03.05515482757
Kol S,Itskovitz-Eldor J,Sever OHSS; Yes there is a strategy to prevent it!Hum ReprodYear: 20001522262227
Symosium Aboulghar M,Update on prediction and management of OHSS. Prevention of OHSSReprod Biomed OnlineYear: 200919334210.1016/S1472-6483(10)60043-019573288
Engmann L,DiLuigi A,Schmidt D,Nulsen J,Maier D,Benadiva C,The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled studyFertil SterilYear: 200889849110.1016/j.fertnstert.2007.02.00217462639
Humaidan P,Ejdrup Bredkjaer H,Westergaard LG,Yding Andersen C,1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled studyFertil SterilYear: 20109384785410.1016/j.fertnstert.2008.12.04219200959
Papanikolaou EG,Verpoest W,Fatemi H,Tarlatzis B,Devroey P,Tournaye H,A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept studyFertil SterilYear: 2011951174117710.1016/j.fertnstert.2010.09.02320979997
Bodri D,Guillen JJ,Galindo A,Mataro D,Pujol A,Coll O,Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort studyFertil SterilYear: 20099136537110.1016/j.fertnstert.2007.11.04918367175
Saragusty J,Arav A,Current progress in oocyte and embryo cryopreservation by slow freezing and vitrificationReproductionYear: 201114111910.1530/REP-10-023620974741
Castillo JC,Dolz M,Bienvenido E,Abad L,Casan EM,Bonilla-Musoles F,Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal supportReprod Biomed OnlineYear: 20102017518110.1016/j.rbmo.2009.11.01820113955
Papanikolaou EG,Kolibianakis EM,Tournaye H,Venetis CA,Fatemi H,Tarlatzis B,Devroey P,Live birth rates after transfer of equal number of blastocysts or cleavage-stage embryos in IVF. A systematic review and meta-analysisHum ReprodYear: 200823919917965420


[Figure ID: F1]
Figure 1 

New proposed algorithm for OHSS prevention and treatment. The upper pathway (traditional) applies to both the GnRH agonist and GnRH antagonist protocol. The lower pathway (innovative) applies only to the GnRH antagonist protocol.

Article Categories:
  • Debate

Previous Document:  Effect of salt and phosphate on the quality of Buffalo and Goat meats.
Next Document:  Osteogenesis imperfecta missense mutations in collagen: structural consequences of a glycine to alan...